Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.52 |
| ▸ | CCND1 | P24385 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 4/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30041985 | 1.00 | CDK4 (0.52) | CDK4CCND1KMT2ASIGMAR1HTR2A | |
| SCHEMBL11012058 | 0.85 | CDK4 (0.65) | CDK4CCND1SIGMAR1HTR2AHTR2C | |
| SCHEMBL4828100 | 0.84 | CDK4 (0.57) | CDK4CCND1KMT2AHTR2AHTR2C | |
| SCHEMBL7052509 | 0.84 | CDK4 (0.57) | CDK4CCND1KMT2AHTR2AHTR2C | |
| SCHEMBL4896448 | 0.83 | CDK4 (0.55) | CDK4CCND1KMT2AHTR2AHTR2C | |
| SCHEMBL15578543 | 0.83 | CDK4 (0.67) | CDK4CCND1SIGMAR1HTR2AHTR2C | |
| SCHEMBL3205345 | 0.80 | CDK4 (0.56) | CDK4CCND1SIGMAR1HTR2AHTR2C | |
| SCHEMBL5944315 | 0.80 | CDK4 (0.52) | CDK4CCND1KMT2AHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL28867138 | 0.79 | CDK4 (0.55) | CDK4CCND1SIGMAR1HTR2AHTR2C | |
| Ammonia Solution, Strong SCHEMBL28783985 | 0.79 | CDK4 (0.55) | CDK4CCND1SIGMAR1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781476-B2 | Serotonin and melatonergic ligands such as 10-(4-Methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide, used for the treatment of psychological disorders, side effect reduction of antipsychotic drugs, neurodegenerative disorders, chemotherapy-induced vomiting and eating disorders | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-08-24 | — | — | US | disclosed |
| US-20100041669-A1 | 4-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-02-18 | — | — | US | disclosed |
| US-20070142398-A1 | Tetracyclic 3-substituted indoles having serotonin receptor affinity | SUVEN LIFE SCIENCES LIMITED (IN) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142398-A1 | Tetracyclic 3-substituted indoles having serotonin receptor affinity | HTR3A, HTR3C, HTR3B | CDK4 2939/4885CCND1 3368/4885KMT2A 2039/4885 |
| US-20100041669-A1 | 4-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR5A, HTR1A | CDK4 1064/4885CCND1 1836/4885KMT2A 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.